Product Description: CLP290 is an orally available activator of the neuron-specific K+-Cl? cotransporter KCC2, displays potential for treatment of a wide range of neurological and psychiatric indications. CLP290 can significantly lower blood arginine-vasopressin (AVP) and glucose levels in STZ (HY-13753) rats[1][2].
Applications: Neuroscience-Neuromodulation
Formula: C19H21FN4O3S
References: [1]Ferrini F, et al. Enhancing KCC2 function counteracts morphine-induced hyperalgesia. Sci Rep. 2017 Jun 20;7(1):3870./[2]Gagnon M, et al. Chloride extrusion enhancers as novel therapeutics for neurological diseases. Nat Med. 2013 Nov;19(11):1524-8./[3]Kim YB, et al. Excitatory GABAergic Action and Increased Vasopressin Synthesis in Hypothalamic Magnocellular Neurosecretory Cells Underlie the High Plasma Level of Vasopressin in Diabetic Rats. Diabetes. 2018 Mar;67(3):486-495.
CAS Number: 1181083-81-7
Molecular Weight: 404.46
Compound Purity: 99.87
Research Area: Neurological Disease
Solubility: DMSO : 33.33 mg/mL (ultrasonic)
Target: Potassium Channel
Deutsch
English
